Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: June 9, 2023
Event: Filing of a Prospectus Supplement to register shares of Class A common stock issued in connection with the acquisition of Cyclica Inc.
Key Financial Metrics
This filing is a current report regarding a corporate transaction and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
- Acquisition Completion: Recursion Canada Inc. (a wholly-owned subsidiary) acquired 100% of the outstanding equity securities of Cyclica Inc. (the "Cyclica Acquisition").
- Share Registration: A Prospectus Supplement was filed to register "Resale Shares" of Recursion Class A common stock issued to certain Cyclica shareholders as consideration for the acquisition.
- Option Exchange: The filing also registered "Option Shares" issuable upon the exercise of options held by current and former Cyclica service providers, which were assumed and exchanged for Recursion options.
Guidance, Outlook, and Risks
Management Commentary: The filing details the execution of a Registration Agreement dated May 25, 2023, requiring Recursion to keep the registration statement effective until all Resale Shares are sold or eligible for public sale under Rule 144.
Risks and Contingencies: The filing references the Registration Agreement and legal opinions regarding the legality of the shares but does not explicitly list new risk factors or contingencies beyond the standard obligations of the registration process.
Investor Verification Checklist
- Verify the terms of the Registration Agreement (Exhibit 4.1) regarding the resale restrictions and obligations for Cyclica shareholders.
- Review the details of the Cyclica Second Amended and Restated Stock Option Plan (Exhibit 4.2) to understand the dilution potential from exchanged options.
- Confirm the total number of Resale Shares and Option Shares registered in the Prospectus Supplement referenced in this filing.
- Check the May 8, 2023 Form 8-K for the initial announcement details of the Cyclica Acquisition.